Equity Overview
Price & Market Data
Price: $3.90
Daily Change: -$0.0565 / 1.45%
Daily Range: $3.90 - $4.06
Market Cap: $481,912,288
Daily Volume: 1,965,730
Performance Metrics
1 Week: 5.33%
1 Month: 17.56%
3 Months: -33.16%
6 Months: 1.80%
1 Year: 29.08%
YTD: -38.85%
Company Details
Employees: 142
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.